Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | SMYD3 | Q9H7B4 | 16/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13854220 | 0.87 | EPHX2 (0.44) | EPHX2SMYD3HTR1ADRD2HTR2A | |
| SCHEMBL13854197 | 0.85 | EPHX2 (0.60) | EPHX2SMYD3HTR1ADRD2HTR2A | |
| SCHEMBL4204194 | 0.83 | EPHX2 (0.61) | EPHX2SMYD3HTR1ADRD2HTR2A | |
| SCHEMBL14497589 | 0.81 | EPHX2 (0.58) | EPHX2SMYD3HTR1ADRD2HTR2A | |
| SCHEMBL4198695 | 0.80 | EPHX2 (0.57) | EPHX2SMYD3HTR1ADRD2HTR2A | |
| SCHEMBL4199097 | 0.80 | SMYD3 (0.45) | EPHX2SMYD3 | |
| SCHEMBL4194804 | 0.79 | EPHX2 (0.53) | EPHX2SMYD3HTR1ADRD2HTR2A | |
| SCHEMBL13854221 | 0.79 | MAPT (0.39) | EPHX2HDAC6 | |
| SCHEMBL29779535 | 0.76 | CRBN (0.58) | EPHX2SMYD3 | |
| SCHEMBL688478 | 0.76 | CRBN (0.58) | EPHX2SMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170079958-A1 | MIF INHIBITORS FOR THE ACUTE OR CHRONIC TREATMENT OF PULMONARY HYPERTENSION | Universite Paris-Saclay (FR) | 2017-03-23 | — | — | US | disclosed |
| US-20090130165-A1 | MIF Inhibitors | CORTICAL PTY LTD | 2009-05-21 | — | — | US | disclosed |
| US-20090130165-A1 | MIF Inhibitors | CORTICAL PTY LTD | 2009-05-21 | — | — | US | disclosed |
| US-20090130165-A1 | MIF Inhibitors | CORTICAL PTY LTD | 2009-05-21 | — | — | US | disclosed |
| CN-101410107-A | MIF inhibitors | CORTICAL PTY LTD (AU) | 2009-04-15 | — | — | CN | disclosed |
| WO-2007070961-A1 | MIF INHIBITORS | CORTICAL PTY LTD (AU) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090130165-A1 | MIF Inhibitors | MIF, MMP12, IL4 | EPHX2 2288/4885SMYD3 4031/4885HTR1A 3948/4885 |
| US-20170079958-A1 | MIF INHIBITORS FOR THE ACUTE OR CHRONIC TREATMENT OF PULMONARY HYPERTENSION | MIF, CCL11, PGF | EPHX2 474/4885SMYD3 3217/4885HTR1A 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.